451 related articles for article (PubMed ID: 22473858)
1. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B.
Lampertico P; Viganò M; Cheroni C; Facchetti F; Invernizzi F; Valveri V; Soffredini R; Abrignani S; De Francesco R; Colombo M
Hepatology; 2013 Mar; 57(3):890-6. PubMed ID: 22473858
[TBL] [Abstract][Full Text] [Related]
2. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.
Sonneveld MJ; Wong VW; Woltman AM; Wong GL; Cakaloglu Y; Zeuzem S; Buster EH; Uitterlinden AG; Hansen BE; Chan HL; Janssen HL
Gastroenterology; 2012 Mar; 142(3):513-520.e1. PubMed ID: 22108195
[TBL] [Abstract][Full Text] [Related]
3. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon.
Boglione L; Cusato J; Allegra S; Esposito I; Patti F; Cariti G; Di Perri G; D'Avolio A
Antiviral Res; 2014 Feb; 102():35-43. PubMed ID: 24316030
[TBL] [Abstract][Full Text] [Related]
4. IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients.
Galmozzi E; Facchetti F; Grossi G; Loglio A; Viganò M; Lunghi G; Colombo M; Lampertico P
Liver Int; 2018 Mar; 38(3):417-423. PubMed ID: 28732143
[TBL] [Abstract][Full Text] [Related]
5. Vitamin D-Binding protein Gene Polymorphism Predicts Pegylated Interferon-Related HBsAg Seroclearance in HBeAg-Negative Thai Chronic Hepatitis B Patients: A Multicentre Study.
Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Treeprasertsuk S; Tanwandee T; Charatcharoenwitthaya P; Thongsawat S; Leerapun A; Piratvisuth T; Boonsirichan R; Bunchorntavakul C; Pattanasirigool C; Pornthisarn B; Tuntipanichteerakul S; Sripariwuth E; Jeamsripong W; Sanpajit T; Poovorawan Y; Komolmit P
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1257-1264. PubMed ID: 31030503
[TBL] [Abstract][Full Text] [Related]
6. HBsAg seroconversion after pegylated interferon alfa 2a rescue in a lamivudine-resistant patient with HBeAg-negative chronic hepatitis B and favourable IL28-B genotype.
Stanzione M; Stornaiuolo G; Rizzo V; Pontarelli A; Gaeta GB
Infez Med; 2016 Jun; 24(2):144-6. PubMed ID: 27367326
[TBL] [Abstract][Full Text] [Related]
7. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
8. Role of HBsAg decline in patients with chronic hepatitis B HBeAg-negative and E genotype treated with pegylated-interferon.
Boglione L; Cusato J; Cariti G; Di Perri G; D'Avolio A
Antiviral Res; 2016 Dec; 136():32-36. PubMed ID: 27793564
[TBL] [Abstract][Full Text] [Related]
9. IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α.
Holmes JA; Nguyen T; Ratnam D; Heerasing NM; Tehan JV; Bonanzinga S; Dev A; Bell S; Pianko S; Chen R; Visvanathan K; Hammond R; Iser D; Rusli F; Sievert W; Desmond PV; Bowden DS; Thompson AJ
J Gastroenterol Hepatol; 2013 May; 28(5):861-6. PubMed ID: 23301835
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 28B polymorphism predicts pegylated interferon plus ribavirin treatment outcome in chronic hepatitis C genotype 4.
De Nicola S; Aghemo A; Rumi MG; Galmozzi E; Valenti L; Soffredini R; De Francesco R; Prati GM; D'Ambrosio R; Cheroni C; Donato MF; Colombo M
Hepatology; 2012 Feb; 55(2):336-42. PubMed ID: 21932415
[TBL] [Abstract][Full Text] [Related]
11. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
Ragheb MM; Nemr NA; Kishk RM; Mandour MF; Abdou MM; Matsuura K; Watanabe T; Tanaka Y
Liver Int; 2014 Jul; 34(6):890-5. PubMed ID: 24102823
[TBL] [Abstract][Full Text] [Related]
12. Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Tangkijvanich P; Treeprasertsuk S; Thaimai P; Wasitthankasem R; Poovorawan Y; Komolmit P
PLoS One; 2015; 10(9):e0137365. PubMed ID: 26339796
[TBL] [Abstract][Full Text] [Related]
13. [IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].
Pár A; Pár G; Tornai I; Szalay F; Várszegi D; Fráter E; Papp M; Lengyel G; Fehér J; Varga M; Gervain J; Schuller J; Nemes Z; Péterfi Z; Tusnádi A; Hunyady B; Haragh A; Szinku Z; Pálinkás L; Berki T; Vincze A; Kisfali P; Melegh B
Orv Hetil; 2013 Aug; 154(32):1261-8. PubMed ID: 23916907
[TBL] [Abstract][Full Text] [Related]
14. Single Nucleotide Polymorphism of Interferon Lambda-4 Gene is not Associated with Treatment Response to Pegylated Interferon in Thai Patients with Chronic Hepatitis B.
Limothai U; Wasitthankasem R; Poovorawan Y; Tangkijvanich P
Asian Pac J Cancer Prev; 2015; 16(13):5515-9. PubMed ID: 26225703
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of pegylated-interferon alpha-2a treatment in patients with HBeAg-positive chronic hepatitis B and partial viral response to nucleoside analogue therapy].
Li MH; Hu LP; Zhang L; Lu Y; Shen G; Wu SL; Chang M; Mu CQ; Wu YZ; Yang M; Song SJ; Zhang SF; Hua WH; Xie Y; Cheng J; Xu DZ
Zhonghua Gan Zang Bing Za Zhi; 2015 Nov; 23(11):826-31. PubMed ID: 26743242
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-28B single nucleotide polymorphism of donors and recipients can predict viral response to pegylated interferon/ribavirin therapy in patients with recurrent hepatitis C after living donor liver transplantation.
Kawaoka T; Takahashi S; Takaki S; Hiramatsu A; Waki K; Hiraga N; Miki D; Tsuge M; Imamura M; Kawakami Y; Aikata H; Ochi H; Onoe T; Tashiro H; Ohdan H; Chayama K
J Gastroenterol Hepatol; 2012 Sep; 27(9):1467-72. PubMed ID: 22432893
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of
Świątek-Kościelna B; Kałużna E; Strauss E; Nowak J; Bereszyńska I; Gowin E; Wysocki J; Rembowska J; Barcińska D; Mozer-Lisewska I; Januszkiewicz-Lewandowska D
World J Gastroenterol; 2017 Jun; 23(21):3815-3824. PubMed ID: 28638221
[TBL] [Abstract][Full Text] [Related]
18. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.
Moucari R; Mackiewicz V; Lada O; Ripault MP; Castelnau C; Martinot-Peignoux M; Dauvergne A; Asselah T; Boyer N; Bedossa P; Valla D; Vidaud M; Nicolas-Chanoine MH; Marcellin P
Hepatology; 2009 Apr; 49(4):1151-7. PubMed ID: 19115222
[TBL] [Abstract][Full Text] [Related]
19. Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.
Ladero JM; Martin EG; Fernández C; Carballo M; Devesa MJ; Martínez C; Suárez A; Díaz-Rubio M; Agúndez JA
J Gastroenterol Hepatol; 2012 Feb; 27(2):279-85. PubMed ID: 21722179
[TBL] [Abstract][Full Text] [Related]
20. No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B.
Wei L; Wedemeyer H; Liaw YF; Chan HL; Piratvisuth T; Marcellin P; Jia J; Tan D; Chow WC; Brunetto MR; Diago M; Gurel S; Morozov V; He H; Zhu Y; Wat C; Surujbally B; Thompson AJ
PLoS One; 2018; 13(7):e0199198. PubMed ID: 30016335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]